|
Mar 31, 2026
|
Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results
|
Read More
|
|
Mar 26, 2026
|
Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026
|
Read More
|
|
Mar 21, 2026
|
Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment
|
Read More
|
|
Feb 17, 2026
|
Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program
|
Read More
|
|
Jan 27, 2026
|
Omeros Announces First Commercial Sales of YARTEMLEA®
|
Read More
|
|
Dec 26, 2025
|
Omeros Announces New Date for YARTEMLEA® Approval Conference Call
|
Read More
|
|
Dec 24, 2025
|
FDA Approves Omeros’ YARTEMLEA® – First and Only Therapy Indicated for TA-TMA
|
Read More
|
|
Dec 1, 2025
|
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)
|
Read More
|
|
Nov 13, 2025
|
Omeros Corporation Reports Third Quarter 2025 Financial Results
|
Read More
|
|
Nov 11, 2025
|
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2025
|
Read More
|
|
Oct 16, 2025
|
Omeros Announces Publication Highlighting Survival Benefits in TA-TMA Patients Treated with Narsoplimab Versus a Well-Matched External Control Group
|
Read More
|
|
Oct 15, 2025
|
Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906)
|
Read More
|
|
Sep 2, 2025
|
Omeros Announces Publication Highlighting Survival Outcomes in TA-TMA Patients Treated with Narsoplimab Under Its Global Expanded Access Program
|
Read More
|
|
Aug 14, 2025
|
Omeros Corporation Reports Second Quarter 2025 Financial Results
|
Read More
|
|
Aug 11, 2025
|
Omeros Corporation to Announce Second Quarter Financial Results on August 14, 2025
|
Read More
|
|
Jul 25, 2025
|
Omeros Corporation Announces Pricing of $22 Million Registered Direct Offering
|
Read More
|
|
Jun 27, 2025
|
Omeros Submits Narsoplimab Marketing Authorization Application to the European Medicines Agency for the Treatment of TA-TMA
|
Read More
|
|
Jun 24, 2025
|
Omeros Announces Webcast Details for Annual Meeting of Shareholders
|
Read More
|
|
May 15, 2025
|
Omeros Corporation Reports First Quarter 2025 Financial Results
|
Read More
|
|
May 12, 2025
|
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2025
|
Read More
|
|
May 12, 2025
|
Omeros Corporation Announces Agreements to Acquire $80.5 Million of its Convertible Senior Notes Due 2026
|
Read More
|
|
May 6, 2025
|
FDA Accepts Resubmission of BLA for Narsoplimab for Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (TA-TMA) and Assigns Late September PDUFA Date
|
Read More
|
|
Apr 10, 2025
|
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
|
Read More
|
|
Apr 8, 2025
|
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
|
Read More
|
|
Mar 31, 2025
|
Omeros Corporation Reports Fourth Quarter and Year-End 2024 Financial Results
|
Read More
|
|
Mar 26, 2025
|
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 31, 2025
|
Read More
|
|
Mar 21, 2025
|
Omeros Corporation Provides Update of Ongoing Zaltenibart Phase 3 PNH Clinical Trial Program
|
Read More
|
|
Mar 13, 2025
|
Omeros Corporation Receives Commitment of Over $4 Million from NIDA for Further Development of the Company’s OMS527 Program to Treat Cocaine Use Disorder
|
Read More
|
|
Feb 20, 2025
|
Omeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMA
|
Read More
|
|
Feb 14, 2025
|
Omeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem Meetings
|
Read More
|
|
Feb 10, 2025
|
Omeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access Program
|
Read More
|
|
Jan 16, 2025
|
Omeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary Endpoint
|
Read More
|
|
Dec 19, 2024
|
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA
|
Read More
|
|
Dec 10, 2024
|
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting
|
Read More
|
|
Dec 2, 2024
|
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
|
Read More
|
|
Nov 21, 2024
|
Omeros Corporation Provides Update on Progress Toward BLA Resubmission
|
Read More
|
|
Nov 13, 2024
|
Omeros Corporation Reports Third Quarter 2024 Financial Results
|
Read More
|
|
Nov 11, 2024
|
Omeros Corporation to Announce Third Quarter Financial Results on November 13, 2024
|
Read More
|
|
Oct 24, 2024
|
FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
|
Read More
|
|
Aug 7, 2024
|
Omeros Corporation Reports Second Quarter 2024 Financial Results
|
Read More
|
|
Aug 5, 2024
|
Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024
|
Read More
|
|
Jun 4, 2024
|
Omeros Announces Webcast Details for Annual Meeting of Shareholders
|
Read More
|
|
Jun 3, 2024
|
Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028
|
Read More
|
|
May 15, 2024
|
Omeros Corporation Reports First Quarter 2024 Financial Results
|
Read More
|
|
May 10, 2024
|
Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024
|
Read More
|
|
May 9, 2024
|
Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress
|
Read More
|
|
Apr 1, 2024
|
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
|
Read More
|
|
Mar 27, 2024
|
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
|
Read More
|
|
Feb 20, 2024
|
Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
|
Read More
|
|
Feb 1, 2024
|
Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust
|
Read More
|
|
Nov 9, 2023
|
Omeros Corporation Reports Third Quarter 2023 Financial Results
|
Read More
|
|
Nov 6, 2023
|
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2023
|
Read More
|
|
Nov 3, 2023
|
Omeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
|
Read More
|
|
Nov 2, 2023
|
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
|
Read More
|
|
Oct 19, 2023
|
Omeros Corporation Hires Andreas Grauer M.D. as Chief Medical Officer
|
Read More
|
|
Oct 16, 2023
|
Omeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA Nephropathy
|
Read More
|
|
Aug 9, 2023
|
Omeros Corporation Reports Second Quarter 2023 Financial Results
|
Read More
|
|
Aug 4, 2023
|
Omeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023
|
Read More
|
|
Jun 21, 2023
|
Omeros Announces Webcast Details for Annual Meeting of Shareholders
|
Read More
|
|
Jun 12, 2023
|
Omeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association Congress
|
Read More
|
|
Jun 1, 2023
|
Omeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) Congress
|
Read More
|
|
May 9, 2023
|
Omeros Corporation Reports First Quarter 2023 Financial Results
|
Read More
|
|
May 4, 2023
|
Omeros Corporation to Announce First Quarter Financial Results on May 9, 2023
|
Read More
|
|
Apr 25, 2023
|
Omeros Corporation Reports Interim Data with Alternative Pathway Inhibitor OMS906 as Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
|
Read More
|
|
Apr 10, 2023
|
Omeros Corporation Awarded $6.69 Million Grant from the National Institute on Drug Abuse for its OMS527 Addiction Program
|
Read More
|
|
Mar 13, 2023
|
Omeros Corporation Reports Fourth Quarter and Year-End 2022 Financial Results
|
Read More
|
|
Mar 10, 2023
|
Omeros Corporation Confirms Absence of Financial Exposure to Silicon Valley Bank
|
Read More
|
|
Mar 7, 2023
|
Omeros Corporation to Announce Fourth Quarter and Year End Financial Results on March 13, 2023
|
Read More
|
|
Feb 6, 2023
|
Omeros Corporation Receives $200 Million Milestone Payment from Rayner Surgical
|
Read More
|
|
Nov 9, 2022
|
Omeros Corporation Reports Third Quarter 2022 Financial Results
|
Read More
|
|
Nov 8, 2022
|
Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab
|
Read More
|
|
Nov 4, 2022
|
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022
|
Read More
|
|
Nov 3, 2022
|
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting
|
Read More
|
|
Oct 3, 2022
|
Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare Trust
|
Read More
|
|
Sep 15, 2022
|
Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID Trial
|
Read More
|
|
Sep 15, 2022
|
I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19
|
Read More
|
|
Aug 17, 2022
|
Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for Narsoplimab
|
Read More
|
|
Aug 9, 2022
|
Omeros Corporation Reports Second Quarter 2022 Financial Results
|
Read More
|
|
Aug 4, 2022
|
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022
|
Read More
|
|
Jul 29, 2022
|
FDA Grants Orphan Drug Designation to Omeros’ MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal Hemoglobinuria
|
Read More
|
|
Jun 15, 2022
|
Omeros Announces Webcast Details for Annual Meeting of Shareholders
|
Read More
|
|
May 10, 2022
|
Omeros Corporation Reports First Quarter 2022 Financial Results
|
Read More
|
|
May 4, 2022
|
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022
|
Read More
|
|
Apr 20, 2022
|
Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMA
|
Read More
|
|
Mar 1, 2022
|
Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial Results
|
Read More
|
|
Feb 24, 2022
|
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022
|
Read More
|
|
Jan 19, 2022
|
Omeros Confirms Submission of Response to FDA Regarding the BLA for Narsoplimab in the Treatment of HSCT-TMA
|
Read More
|
|
Dec 23, 2021
|
Omeros Completes Sale of OMIDRIA® Franchise to Rayner Surgical
|
Read More
|
|
Dec 2, 2021
|
Omeros Announces Agreement to Sell OMIDRIA® Franchise to Rayner Surgical in a Transaction Valued in Excess of $1 Billion
|
Read More
|
|
Nov 9, 2021
|
Omeros Corporation Reports Third Quarter 2021 Financial Results
|
Read More
|
|
Nov 5, 2021
|
Omeros Announces Results From Nearly Three-Year Follow-up of Patients in Phase 2 IgA Nephropathy Trial
|
Read More
|
|
Nov 5, 2021
|
Omeros’ Narsoplimab Stabilized Kidney Function and Reduced Urinary Complement Proteins in a Patient with IgA Vasculitis
|
Read More
|
|
Nov 4, 2021
|
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2021
|
Read More
|
|
Oct 18, 2021
|
Omeros Receives Complete Response Letter from FDA for Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
|
Read More
|
|
Oct 1, 2021
|
Omeros Provides Regulatory Update on Biologics License Application for Narsoplimab in the Treatment of HSCT-TMA
|
Read More
|
|
Aug 9, 2021
|
Omeros Corporation Reports Second Quarter 2021 Financial Results
|
Read More
|
|
Aug 3, 2021
|
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2021
|
Read More
|
|
Jun 14, 2021
|
Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at 2021 Annual Congress of the European Hematology Association
|
Read More
|
|
Jun 10, 2021
|
Omeros Announces Publication Detailing the Mechanism of Action of PDE7 In Nicotine Addiction
|
Read More
|
|
Jun 9, 2021
|
Omeros to Present at the BofA 2021 Napa BioPharma Virtual Conference
|
Read More
|
|
Jun 9, 2021
|
Omeros Announces Preliminary Results from Phase 1 Clinical Trial of OMS906
|
Read More
|
|
May 28, 2021
|
Omeros Announces Preliminary Results from Additional Critically Ill COVID-19 Patients Treated with Narsoplimab
|
Read More
|
|
May 20, 2021
|
Omeros Announces Extension of FDA Review Period for Narsoplimab in HSCT-TMA
|
Read More
|
|
May 13, 2021
|
Omeros’ Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association Congress
|
Read More
|
|
May 10, 2021
|
Omeros Corporation Reports First Quarter 2021 Financial Results
|
Read More
|
|
May 5, 2021
|
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2021
|
Read More
|
|
May 4, 2021
|
Omeros Corporation Announces Approval of ICD-10 Codes for HSCT-TMA Diagnosis and for Narsoplimab Administration
|
Read More
|
|
Mar 23, 2021
|
Omeros and Quantum Leap Announce First Patients Dosed with Narsoplimab in the I-SPY COVID-19 Trial
|
Read More
|
|
Mar 1, 2021
|
Omeros Corporation Reports Fourth Quarter and Year-End 2020 Financial Results
|
Read More
|
|
Feb 25, 2021
|
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on March 1, 2021
|
Read More
|
|
Jan 26, 2021
|
Omeros Hires Nadia Dac as Chief Commercial Officer
|
Read More
|
|
Jan 19, 2021
|
Biologics License Application for Narsoplimab in HSCT-TMA Accepted for Priority Review by U.S. FDA
|
Read More
|
|
Jan 11, 2021
|
Omeros to Present at the 39th Annual J.P. Morgan Healthcare Conference
|
Read More
|
|
Dec 3, 2020
|
CMS Confirms Continued Separate Payment for Omeros’ FDA-Approved OMIDRIA® in Ambulatory Surgery Centers
|
Read More
|
|
Nov 18, 2020
|
Omeros Submits its Biologics License Application to U.S. FDA for Narsoplimab in HSCT-TMA
|
Read More
|
|
Nov 9, 2020
|
Omeros Corporation Reports Third Quarter 2020 Financial Results
|
Read More
|
|
Nov 5, 2020
|
Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2020
|
Read More
|
|
Oct 28, 2020
|
Omeros Participates in Investor Conference Focused on COVID-19 Therapeutics in Development
|
Read More
|
|
Oct 22, 2020
|
Omeros Reports Final Efficacy and Safety Data from the Narsoplimab Pivotal Trial in HSCT-TMA
|
Read More
|
|
Oct 16, 2020
|
Omeros’ OMS906 Data Presented at Complement-based Drug Development Summit
|
Read More
|
|
Oct 15, 2020
|
Omeros Schedules Webcast to Present Final Efficacy Results from Narsoplimab BLA for the Treatment of HSCT-TMA
|
Read More
|
|
Oct 1, 2020
|
Omeros Provides Update on Separate Payment for OMIDRIA® in the ASCs
|
Read More
|
|
Sep 11, 2020
|
Omeros to Present at the Cantor Virtual Global Healthcare Conference
|
Read More
|
|
Sep 3, 2020
|
Expert Panel Points to Central Role of Endothelial Injury and Lectin Pathway Activation in Critically Ill COVID-19 Patients
|
Read More
|
|
Aug 31, 2020
|
Omeros’ Investigational New Drug Application for OMS906 Cleared by FDA
|
Read More
|
|
Aug 12, 2020
|
Omeros Announces Pricing of Public Offerings
|
Read More
|
|
Aug 10, 2020
|
Omeros Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes
|
Read More
|
|
Aug 10, 2020
|
Omeros Corporation Reports Second Quarter 2020 Financial Results
|
Read More
|
|
Aug 10, 2020
|
Omeros Corporation Reports Recovery and Survival of All Patients in Study Evaluating Narsoplimab for Treatment of COVID-19-Associated Acute Respiratory Distress Syndrome
|
Read More
|
|
Jun 12, 2020
|
Omeros’ Narsoplimab Pivotal Trial Data Shared in Oral Presentation at Annual European Hematology Association Congress
|
Read More
|
|
Jun 11, 2020
|
Omeros’ Narsoplimab Pivotal Trial Data to be Shared as an Oral Presentation at Annual European Hematology Association Congress
|
Read More
|
|
May 14, 2020
|
Omeros Corporation Announces Presentation of Narsoplimab Pivotal Trial Data at Upcoming European Hematology Association Annual Congress
|
Read More
|
|
May 11, 2020
|
Omeros Corporation Reports First Quarter 2020 Financial Results
|
Read More
|
|
May 5, 2020
|
Omeros Corporation to Announce First Quarter Financial Results on May 11, 2020
|
Read More
|
|
Mar 2, 2020
|
Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results
|
Read More
|
|
Mar 2, 2020
|
Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA
|
Read More
|
|
Feb 24, 2020
|
Omeros Corporation to Announce Fourth Quarter and Year-End 2019 Financial Results on March 2, 2020
|
Read More
|
|
Feb 11, 2020
|
Omeros Corporation Appoints Former Amazon Treasurer Kurt Zumwalt to Board of Directors
|
Read More
|
|
Dec 18, 2019
|
myTomorrows and Omeros Corporation Collaborate to Provide an Expanded Access Program for Narsoplimab
|
Read More
|
|
Dec 16, 2019
|
Omeros’ Newly Presented GPR174 Immuno-oncology Data at ESMO Immuno-Oncology Congress Show Inhibition of Both Checkpoint and Tumor-Promoting Factors
|
Read More
|
|
Dec 13, 2019
|
Omeros Announces Full Exercise and Closing of Underwriter’s Option to Purchase Additional Shares
|
Read More
|
|
Dec 10, 2019
|
Omeros to Present GPR174 Data at the European Society for Medical Oncology 2019 Immuno-Oncology Congress in Geneva
|
Read More
|
|
Dec 5, 2019
|
Omeros Announces Pricing of Upsized Public Offering of Common Stock
|
Read More
|
|
Dec 4, 2019
|
Omeros Announces Proposed Public Offering of Common Stock
|
Read More
|
|
Dec 4, 2019
|
Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients Treated with Narsoplimab
|
Read More
|
|
Nov 20, 2019
|
Omeros’ New GPR174 Immuno-oncology Data Presented at the American Association for Cancer Research Conference In Boston Now Available Online
|
Read More
|
|
Nov 19, 2019
|
Omeros Presents New GPR174 Immuno-oncology Data Today at the American Association for Cancer Research Conference in Boston
|
Read More
|
|
Nov 12, 2019
|
Omeros Corporation Reports Third Quarter 2019 Financial Results
|
Read More
|
|
Nov 8, 2019
|
Omeros to Present GPR174 Data at Upcoming American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy
|
Read More
|
|
Nov 7, 2019
|
Omeros Scientists Win 2019 Prix Galien Research Award
|
Read More
|
|
Nov 6, 2019
|
Omeros Corporation to Announce Third Quarter 2019 Financial Results on November 12, 2019
|
Read More
|
|
Nov 4, 2019
|
Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain
|
Read More
|
|
Oct 29, 2019
|
Omeros’ Narsoplimab Receives Positive Opinion from European Medicines Agency for Pediatric Investigation Plan Required for MAA Submission
|
Read More
|
|
Oct 28, 2019
|
Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA
|
Read More
|
|
Oct 1, 2019
|
Product-Specific J-Code for Omeros’ OMIDRIA® is Now in Effect
|
Read More
|
|
Sep 25, 2019
|
Omeros Announces Publication of Study Showing that Inhibition of MASP-2, the Key Enzyme of the Complement System’s Lectin Pathway, Protects Against Renal Injury Caused by Proteinuria
|
Read More
|
|
Sep 16, 2019
|
Omeros Corporation Announces Positive Results from Phase 1 Study of its Lead PDE7 Inhibitor in Development for Addiction
|
Read More
|
|
Sep 11, 2019
|
FDA Confirms Omeros’ Schedule for Rolling Review of the Company’s BLA for Narsoplimab in the Treatment of HSCT-TMA
|
Read More
|
|
Sep 10, 2019
|
Omeros Discovers New Cancer-Immunity Pathways Controlled by GPR174
|
Read More
|
|
Sep 6, 2019
|
Omeros to Present at the H.C. Wainwright 21st Annual Global Investment Conference
|
Read More
|
|
Aug 9, 2019
|
Omeros to Present at the 2019 Wedbush PacGrow Healthcare Conference
|
Read More
|
|
Aug 8, 2019
|
Omeros Corporation Reports Second Quarter 2019 Financial Results
|
Read More
|
|
Aug 5, 2019
|
Omeros Corporation to Announce Second Quarter 2019 Financial Results on August 8, 2019
|
Read More
|
|
Jul 31, 2019
|
Omeros and Lonza Enter Long-Term Manufacturing Agreement for Commercial Supply of Narsoplimab
|
Read More
|
|
Jul 24, 2019
|
Omeros’ OMIDRIA® Receives Product-Specific J-Code from CMS
|
Read More
|
|
Jul 11, 2019
|
Omeros Announces Agreement with FDA on Primary Endpoint for Narsoplimab BLA in Stem Cell Transplant-Associated TMA
|
Read More
|
|
Jun 5, 2019
|
Omeros Corporation Announces Assignment of Rapporteurs for European Marketing Authorization Application for Narsoplimab for Treatment of HSCT-TMA
|
Read More
|
|
May 15, 2019
|
Omeros to Present at the UBS Global Healthcare Conference
|
Read More
|
|
May 9, 2019
|
Omeros Corporation Reports First Quarter 2019 Financial Results
|
Read More
|
|
May 7, 2019
|
Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with OMIDRIA® Presented at American Society of Cataract and Refractive Surgery Annual Meeting
|
Read More
|
|
May 6, 2019
|
Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019
|
Read More
|
|
May 1, 2019
|
Omeros Corporation Announces Presentation of OMIDRIA® Real-World Data at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting
|
Read More
|
|
Apr 3, 2019
|
Omeros Corporation Announces EBMT Case Report of Resolution of Gastrointestinal Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Following Narsoplimab Treatment
|
Read More
|
|
Mar 19, 2019
|
Omeros Corporation Announces Upcoming Educational Event at the Annual Meeting of the European Society of Blood and Marrow Transplantation
|
Read More
|
|
Mar 1, 2019
|
Omeros Corporation Reports Fourth Quarter and Year-End 2018 Financial Results
|
Read More
|
|
Feb 26, 2019
|
Omeros Corporation to Announce Fourth Quarter and Year-End 2018 Financial Results on March 1, 2019
|
Read More
|
|
Feb 20, 2019
|
Omeros Corporation Announces USAN and INN Selection of Nonproprietary Name for OMS721
|
Read More
|
|
Feb 14, 2019
|
Omeros Corporation Streamlines Path to Biologics License Application for OMS721 in HSCT-TMA Following Meeting with FDA
|
Read More
|
|
Feb 12, 2019
|
Omeros Corporation Appoints Thomas F. Bumol, Ph.D., to Board of Directors
|
Read More
|
|
Jan 17, 2019
|
Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy
|
Read More
|
|
Jan 14, 2019
|
Omeros Corporation Announces Record High Quarterly Revenue Results for the Fourth Quarter 2018
|
Read More
|
|
Dec 20, 2018
|
Omeros Establishes Independent Academic Leadership Committee for its OMS721 Phase 3 Clinical Program in IgA Nephropathy
|
Read More
|
|
Dec 11, 2018
|
Omeros Announces Research Collaboration with University of Cambridge
|
Read More
|
|
Dec 6, 2018
|
Omeros Announces Clinical Strategy to Accelerate Pediatric Development of OMS721 for the Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy (HSCT-TMA)
|
Read More
|
|
Dec 3, 2018
|
Omeros Announces Additions to Senior Management Team
|
Read More
|
|
Nov 9, 2018
|
Omeros Announces Pricing of $210 Million Offering of Convertible Senior Notes Due 2023
|
Read More
|
|
Nov 8, 2018
|
Omeros Announces Proposed $210 Million Offering of Convertible Senior Notes Due 2023
|
Read More
|
|
Nov 8, 2018
|
Omeros Corporation Reports Third Quarter 2018 Financial Results
|
Read More
|
|
Nov 5, 2018
|
Omeros Corporation to Announce Third Quarter 2018 Financial Results on November 9, 2018
|
Read More
|
|
Oct 23, 2018
|
FDA Grants Orphan Drug Designation to Omeros’ OMS721 for Treatment of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
|
Read More
|
|
Oct 1, 2018
|
Omeros Corporation Announces Additional Positive Data for OMS721 in IgA Nephropathy
|
Read More
|
|
Oct 1, 2018
|
Omeros Corporation Announces Reinstatement of Pass-Through Status for OMIDRIA®
|
Read More
|
|
Sep 27, 2018
|
Omeros to Present at the 2018 Cantor Global Healthcare Conference
|
Read More
|
|
Sep 7, 2018
|
Omeros to Present at the Morgan Stanley Global Healthcare Conference
|
Read More
|
|
Aug 28, 2018
|
European Commission Designates OMS721 as an Orphan Medicinal Product for Treatment in Hematopoietic Stem Cell Transplantation
|
Read More
|
|
Aug 10, 2018
|
Omeros to Present at the 2018 Wedbush PacGrow Healthcare Conference
|
Read More
|
|
Aug 9, 2018
|
Omeros Corporation Reports Second Quarter 2018 Financial Results
|
Read More
|
|
Aug 3, 2018
|
Omeros Corporation to Announce Second Quarter 2018 Financial Results on August 9, 2018
|
Read More
|
|
Aug 2, 2018
|
Omeros Hires Former Sanofi Global Development Head as Chief Medical Officer
|
Read More
|
|
Jul 26, 2018
|
Sandoz Amends ANDA to Not Seek Approval for Generic Version of OMIDRIA Until Patents for Omeros’ Drug Expire
|
Read More
|
|
Jul 25, 2018
|
Omeros’ OMS721 Receives European Orphan Drug Designation Positive Opinion for Treatment in Hematopoietic Stem Cell Transplantation
|
Read More
|
|
Jul 23, 2018
|
Omeros Corporation Initiates Sales of OMIDRIA® in Europe
|
Read More
|
|
Jul 17, 2018
|
Omeros Initiates Dosing in Phase 1 Clinical Trial for OMS527 Targeting Addiction
|
Read More
|
|
Jun 27, 2018
|
Omeros Obtains Approval to Initiate Phase 1 Clinical Trial for its OMS527 Addiction Treatment
|
Read More
|
|
May 24, 2018
|
Omeros Announces Settlement of Infringement Suit Against ANDA Filer Lupin
|
Read More
|
|
May 10, 2018
|
Omeros Corporation Reports First Quarter 2018 Financial Results
|
Read More
|
|
May 7, 2018
|
Omeros Corporation to Announce First Quarter 2018 Financial Results on May 10, 2018
|
Read More
|
|
Apr 26, 2018
|
FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of High-Risk Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
|
Read More
|
|
Apr 19, 2018
|
Additional Clinical Studies Supporting the Benefits of OMIDRIA® Presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting
|
Read More
|
|
Apr 13, 2018
|
Omeros Corporation Announces Upcoming Presentations of New Data on OMIDRIA® at the American Society of Cataract and Refractive Surgery Meeting
|
Read More
|
|
Apr 12, 2018
|
OMIDRIA® Added to Veterans Health Administration National Formulary
|
Read More
|
|
Apr 11, 2018
|
Omeros Announces Amendment of Credit Facility
|
Read More
|
|
Mar 1, 2018
|
Omeros Corporation Reports Fourth Quarter and Year-End 2017 Financial Results
|
Read More
|
|
Feb 26, 2018
|
Omeros Corporation to Announce Fourth Quarter and Year-End 2017 Financial Results on March 1, 2018
|
Read More
|
|
Feb 15, 2018
|
Omeros Reports Significant Improvement in Overall Survival Data in OMS721-Treated Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
|
Read More
|
|
Jan 22, 2018
|
European Medicines Agency Issues Orphan Drug Designation Positive Opinion for Omeros’ OMS721 in the Treatment of IgA Nephropathy
|
Read More
|
|
Jan 3, 2018
|
Omeros Corporation Reaches Agreement with FDA on OMS721 Phase 3 Trial Protocol for IgA Nephropathy
|
Read More
|
|
Dec 12, 2017
|
Omeros Corporation Announces FDA Approval of OMIDRIA® for Use in Pediatric Patients
|
Read More
|
|
Nov 9, 2017
|
Omeros Corporation Reports Third Quarter 2017 Financial Results
|
Read More
|
|
Nov 6, 2017
|
Extended Improvement in OMS721-Treated Patients with IgA Nephropathy Presented at American Society of Nephrology Annual Meeting
|
Read More
|
|
Nov 6, 2017
|
Omeros Corporation to Announce Third Quarter 2017 Financial Results on November 9, 2017
|
Read More
|
|
Nov 1, 2017
|
Omeros Announces Upcoming Presentation of Clinical OMS721 Data at the American Society of Nephrology Annual Meeting
|
Read More
|
|
Oct 26, 2017
|
Omeros Reports Additional and Consistently Positive Data for OMS721 in Patients with Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy
|
Read More
|
|
Oct 20, 2017
|
Report of Successful OMS721 Treatment of Patient with Both Stem Cell Transplant-Associated Thrombotic Microangiopathy and Graft-versus-Host Disease Presented at EBMT Annual Meeting
|
Read More
|
|
Oct 16, 2017
|
Omeros Announces Upcoming Presentation of Clinical OMS721 Data at European Society for Blood and Marrow Transplantation
|
Read More
|
|
Oct 5, 2017
|
Omeros Announces Settlement of Infringement Suit Against ANDA Filer Par
|
Read More
|
|
Aug 23, 2017
|
Omeros Responds to Statnews.com Story
|
Read More
|
|
Aug 21, 2017
|
Omeros Closes $68.3 Million Public Offering of Common Stock
|
Read More
|
|
Aug 15, 2017
|
Omeros Announces Pricing of Public Offering of Common Stock
|
Read More
|
|
Aug 14, 2017
|
Omeros Announces Public Offering of Common Stock
|
Read More
|
|
Aug 14, 2017
|
Omeros Data Show Continued Improvement in Patients with IgA Nephropathy Treated with OMS721
|
Read More
|
|
Aug 10, 2017
|
Omeros to Present at the 2017 Wedbush PacGrow Healthcare Conference
|
Read More
|
|
Aug 8, 2017
|
Omeros Corporation Reports Second Quarter 2017 Financial Results
|
Read More
|
|
Aug 4, 2017
|
FDA Grants Orphan Drug Designation to Omeros’ OMS721 for Treatment of IgA Nephropathy
|
Read More
|
|
Aug 2, 2017
|
Omeros Corporation to Announce Second Quarter 2017 Financial Results on August 8, 2017
|
Read More
|
|
Jun 29, 2017
|
Omeros Releases Statement in Response to Recent False Report
|
Read More
|
|
Jun 13, 2017
|
FDA Grants Breakthrough Therapy Designation to Omeros’ MASP-2 Inhibitor OMS721 for the Treatment of IgA Nephropathy
|
Read More
|
|
Jun 1, 2017
|
Omeros Announces OMS721 Presentation at 54th ERA-EDTA Congress
|
Read More
|
|
May 17, 2017
|
Omeros Announces Completion of IgA Nephropathy Cohort in OMS721 Phase 2 Clinical Trial
|
Read More
|
|
May 10, 2017
|
Omeros Corporation Reports First Quarter 2017 Financial Results
|
Read More
|
|
May 3, 2017
|
Omeros Corporation to Announce First Quarter 2017 Financial Results on May 10, 2017
|
Read More
|
|
Apr 3, 2017
|
Omeros to Present at the Needham Healthcare Conference
|
Read More
|
|
Mar 30, 2017
|
Omeros Reports More Positive Data in OMS721 Phase 2 Trial in Renal Diseases
|
Read More
|
|
Mar 28, 2017
|
Omeros Announces OMS721 Presentation at Annual Meeting of the European Society for Blood and Marrow Transplantation
|
Read More
|
|
Mar 27, 2017
|
Omeros to Present Results from Dose-Ranging Stage of OMS721 Clinical Trial in Atypical Hemolytic Uremic Syndrome at World Congress of Nephrology
|
Read More
|
|
Mar 16, 2017
|
Omeros Corporation Reports Fourth Quarter and Year-End 2016 Financial Results
|
Read More
|
|
Mar 10, 2017
|
Omeros Corporation to Announce Fourth Quarter and Year-End 2016 Financial Results on March 16, 2017
|
Read More
|
|
Mar 2, 2017
|
Omeros to Present at the Cowen and Company Annual Health Care Conference
|
Read More
|
|
Mar 1, 2017
|
Omeros Reports Additional Positive Results from OMS721 Phase 2 Trial in Patients with Stem Cell Transplant-Associated Thrombotic Microangiopathy
|
Read More
|
|
Dec 7, 2016
|
Data from Omeros’ OMS721 Phase 2 Clinical Trial in Patients with Stem Cell Transplant-Associated TMA to be Presented at International Transplant Conference
|
Read More
|
|
Dec 6, 2016
|
Omeros Extending Compassionate Use for Pediatric Patient No Longer Requiring Dialysis after OMS721 Treatment
|
Read More
|
|
Dec 5, 2016
|
Omeros’ Proprietary Orphan GPCR Program Delivers New Target and Approach in Cancer Immunotherapy
|
Read More
|
|
Nov 30, 2016
|
International Consortium of Complement Experts Receives €1.3 Million Grant to Study Role of MASP-2 and Lectin Pathway in Traumatic Brain Injury
|
Read More
|
|
Nov 21, 2016
|
Omeros Announces Successful Outcome of OMIDRIA® Pediatric Cataract Trial
|
Read More
|
|
Nov 10, 2016
|
Single Dose of Omeros’ Lead MASP-3 Inhibitor OMS906 Shows Multi-Week Blockade of the Alternative Pathway
|
Read More
|
|
Nov 9, 2016
|
Omeros Corporation Reports Third Quarter 2016 Financial Results
|
Read More
|
|
Nov 7, 2016
|
Omeros Corporation to Announce Third Quarter 2016 Financial Results on November 9, 2016
|
Read More
|
|
Nov 4, 2016
|
Omeros Announces Completion of Initial Funding under $125 Million Credit Facility
|
Read More
|
|
Nov 3, 2016
|
Omeros Files Orphan Drug Application for OMS721 in Immunoglobulin A Nephropathy
|
Read More
|
|
Nov 2, 2016
|
Omeros Announces Positive Data from Phase 2 Clinical Trial Evaluating PPAR-Gamma Agonist in Heroin Users Treated with Buprenorphine/Naloxone
|
Read More
|
|
Oct 31, 2016
|
Omeros Requests Fast Track Designation for OMS721 for the Treatment of IgA Nephropathy
|
Read More
|
|
Oct 27, 2016
|
Omeros Announces $125 Million New Credit Facility
|
Read More
|
|
Oct 20, 2016
|
Omeros Announces Positive Data from OMS721 Phase 2 Trial in Patients with Stem Cell Transplant-Associated Thrombotic Microangiopathy
|
Read More
|
|
Oct 19, 2016
|
Omeros Announces Positive Data from Phase 2 Clinical Trial Evaluating PPAR-gamma Agonist in Cocaine Abuse
|
Read More
|
|
Oct 17, 2016
|
Omeros Announces Positive Data from OMS721 Phase 2 Clinical Trial in Renal Diseases
|
Read More
|
|
Sep 8, 2016
|
Omeros’ MASP-2 Antibody Preserves Brain Tissue and Function in Stroke Models
|
Read More
|
|
Aug 12, 2016
|
Omeros to Present at the 2016 Wedbush PacGrow Healthcare Conference
|
Read More
|
|
Aug 11, 2016
|
Omeros Announces Pricing of Public Offering of Common Stock
|
Read More
|
|
Aug 10, 2016
|
Omeros Announces Public Offering of Common Stock
|
Read More
|
|
Aug 10, 2016
|
Omeros’ Lead MASP-3 Inhibitor OMS906 Demonstrates Efficacy in Paroxysmal Nocturnal Hemoglobinuria Model
|
Read More
|
|
Aug 9, 2016
|
Omeros Corporation Reports Second Quarter 2016 Financial Results
|
Read More
|
|
Aug 4, 2016
|
Omeros Corporation to Announce Second Quarter 2016 Financial Results on August 9, 2016
|
Read More
|
|
Aug 4, 2016
|
Omeros’ Lead MASP-3 Inhibitor OMS906 Demonstrates Blockade of the Alternative Pathway of Complement System
|
Read More
|
|
Jul 28, 2016
|
Omeros Corporation Confirms OMS721 Phase 3 Development Plan with European Medicines Agency
|
Read More
|
|
Jul 7, 2016
|
Omeros to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
|
Read More
|
|
Jun 29, 2016
|
Omeros Corporation Announces Completion of Patient Enrollment in Pediatric Trial of OMIDRIA®
|
Read More
|
|
May 17, 2016
|
Omeros Announces Debt Financing Transaction for $20 Million in Additional Funds
|
Read More
|
|
May 10, 2016
|
Omeros Corporation Reports First Quarter 2016 Financial Results
|
Read More
|
|
May 10, 2016
|
Leonard M. Blum Joins Omeros to Lead Business and Commercial Activities
|
Read More
|
|
May 10, 2016
|
Omeros Corporation Announces Exclusive Middle East Distribution Agreement for OMIDRIA®
|
Read More
|
|
May 4, 2016
|
Omeros Corporation to Announce First Quarter 2016 Financial Results on May 10, 2016
|
Read More
|
|
Apr 26, 2016
|
Omeros Corporation Announces Independent Studies with OMIDRIA® to Be Presented at Upcoming Ophthalmology Congresses
|
Read More
|
|
Apr 20, 2016
|
Patient Dosing Initiated for OMS721 Phase 2 Program in Renal Diseases
|
Read More
|
|
Apr 7, 2016
|
Omeros to Present at the 15th Annual Needham Healthcare Conference
|
Read More
|
|
Mar 8, 2016
|
Omeros Corporation Initiates its Phase 3 Program for OMS721 in aHUS Following Meeting with FDA
|
Read More
|
|
Mar 7, 2016
|
Omeros Corporation Reports Fourth Quarter and Year-End 2015 Financial Results
|
Read More
|
|
Mar 3, 2016
|
Omeros to Present at the Cowen and Company 36th Annual Health Care Conference
|
Read More
|
|
Mar 2, 2016
|
Omeros Corporation to Announce Fourth Quarter and Year-End 2015 Financial Results on March 8, 2016
|
Read More
|
|
Feb 24, 2016
|
Physicians Increasingly Seek Access to OMS721 Compassionate Use Program
|
Read More
|
|
Jan 15, 2016
|
Disclosure of Omidria Post-Launch Study Findings to Occur at Hawaiian Eye and Retina Conference
|
Read More
|
|
Jan 6, 2016
|
Omeros Announces $70 Million New Credit Facility and Conversion of Contract Sales Force to In-House Team
|
Read More
|
|
Nov 9, 2015
|
Omeros Corporation Reports Third Quarter 2015 Financial Results
|
Read More
|
|
Nov 2, 2015
|
Omeros Corporation to Announce Third Quarter 2015 Financial Results on November 9, 2015
|
Read More
|
|
Oct 15, 2015
|
Omeros Announces OMIDRIAssure™ to Expand Patient Access to Omidria®
|
Read More
|
|
Sep 3, 2015
|
Omeros Files Infringement Suits Against Par
|
Read More
|
|
Aug 18, 2015
|
Omeros Announces Additional Positive Data in OMS721 Phase 2 Clinical Trial
|
Read More
|
|
Aug 17, 2015
|
Omeros Announces Plan to File Infringement Suit Against ANDA Filer
|
Read More
|
|
Aug 10, 2015
|
Omeros Corporation Reports Second Quarter 2015 Financial Results
|
Read More
|
|
Aug 7, 2015
|
Omeros to Present at the 2015 Wedbush PacGrow Healthcare Conference
|
Read More
|
|
Aug 3, 2015
|
Omidria® Approved for Commercialization Throughout the European Union and Additional Countries
|
Read More
|
|
Jul 31, 2015
|
Omeros Corporation to Announce Second Quarter 2015 Financial Results on August 10, 2015
|
Read More
|
|
Jul 23, 2015
|
FDA Grants "Fast Track" to Omeros' Complement Inhibitor OMS721 for aHUS
|
Read More
|
|
Jun 17, 2015
|
Rajiv Shah, M.D., Appointed to Omeros' Board of Directors
|
Read More
|
|
Jun 16, 2015
|
Omeros Announces Exclusive License Agreement for Omeros' Arthroscopic Product OMS103
|
Read More
|
|
May 22, 2015
|
Omidria® Receives Positive Opinion from European Medicines Agency's Committee for Medicinal Products for Human Use
|
Read More
|
|
May 11, 2015
|
Omeros Corporation Reports First Quarter 2015 Financial Results
|
Read More
|
|
May 5, 2015
|
Omeros Corporation to Announce First Quarter 2015 Financial Results on May 11, 2015
|
Read More
|
|
Apr 14, 2015
|
European Regulatory Authority Approves Clinical Investigator's Request for Compassionate Use with Omeros Corporation's OMS721
|
Read More
|
|
Apr 9, 2015
|
Omeros to Present at the 14th Annual Needham Healthcare Conference
|
Read More
|
|
Apr 2, 2015
|
Omeros Corporation Announces the U.S. Commercial Launch of Omidria™
|
Read More
|
|
Mar 16, 2015
|
Omeros Corporation Reports Fourth Quarter and Year-End 2014 Financial Results
|
Read More
|
|
Mar 9, 2015
|
Omeros Corporation to Announce Fourth Quarter and Full-Year 2014 Financial Results on March 16, 2015
|
Read More
|
|
Feb 19, 2015
|
Omeros Corporation's Phase 2 OMS721 Trial Resulting in Extended Access for Compassionate Use
|
Read More
|
|
Feb 3, 2015
|
Omeros Closes $84 Million Public Offering of Common Stock and Pre-Funded Warrants
|
Read More
|
|
Jan 29, 2015
|
Omeros Prices $75 Million Public Offering of Common Stock and Pre-Funded Warrants
|
Read More
|
|
Jan 28, 2015
|
Omeros Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
|
Read More
|
|
Nov 19, 2014
|
OMS721 Inhibits Thrombus Formation in Sera from aHUS Patients
|
Read More
|
|
Nov 10, 2014
|
Omeros Corporation Reports Third Quarter 2014 Financial Results
|
Read More
|
|
Nov 6, 2014
|
Omeros Announces Positive Data for MASP-2 Inhibitor in Experimental Model of Stroke
|
Read More
|
|
Nov 4, 2014
|
Omeros Corporation to Announce Third Quarter 2014 Financial Results on November 10, 2014
|
Read More
|
|
Oct 30, 2014
|
Omidria™ Granted Pass-Through Reimbursement Status from CMS
|
Read More
|
|
Oct 21, 2014
|
Omeros Provides Update on PDE10 Inhibitor Program
|
Read More
|
|
Aug 11, 2014
|
Omeros Corporation Reports Second Quarter 2014 Financial Results
|
Read More
|
|
Aug 8, 2014
|
Omeros to Present at the Wedbush PacGrow 2014 Life Sciences Management Access Conference
|
Read More
|
|
Jun 2, 2014
|
Omeros Receives FDA Approval of Omidria™ for Use in Cataract and Other Intraocular Lens Replacement Procedures
|
Read More
|
|
May 12, 2014
|
Omeros Corporation Reports First Quarter 2014 Financial Results
|
Read More
|
|
Apr 7, 2014
|
Omeros to Present at the 13th Annual Needham Healthcare Conference
|
Read More
|
|
Apr 3, 2014
|
Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies
|
Read More
|
|
Apr 1, 2014
|
Omeros Invited to Present on OMS824 Phase 2 Clinical Program at the Schizophrenia International Research Conference
|
Read More
|
|
Mar 21, 2014
|
Omeros to Present at BioCentury Future Leaders in the Biotech Industry Conference
|
Read More
|
|
Mar 19, 2014
|
Omeros Closes $40.25 Million Public Offering of Common Stock
|
Read More
|
|
Mar 14, 2014
|
Omeros Prices $35.0 Million Public Offering of Common Stock
|
Read More
|
|
Mar 13, 2014
|
Omeros Announces Proposed Public Offering of Common Stock
|
Read More
|
|
Mar 13, 2014
|
Omeros Corporation Reports Fourth Quarter and Year-End 2013 Financial Results
|
Read More
|
|
Mar 10, 2014
|
Omeros Announces Positive OMS721 Data in Serum from Patients with aHUS
|
Read More
|
|
Mar 6, 2014
|
Omeros Reports Additional Positive Data from its OMS824 Phase 2a Schizophrenia Clinical Trial
|
Read More
|
|
Mar 5, 2014
|
Omeros Closes $32 Million Debt Financing, Receiving $12.6 Million in New Funds
|
Read More
|
|
Mar 4, 2014
|
Omeros Submits IND to Advance OMS721 Phase 2 Clinical Program
|
Read More
|
|
Feb 26, 2014
|
Omeros to Present at Cowen and Company 34th Annual Health Care Conference
|
Read More
|
|
Feb 19, 2014
|
Omeros Announces Enrollment in Second Phase 2 Clinical Trial with OMS824
|
Read More
|
|
Feb 11, 2014
|
Omeros Reports Additional Positive Phase 1 Clinical Data for OMS824 for the Treatment of Cognitive Disorders
|
Read More
|
|
Feb 5, 2014
|
FDA Grants Fast Track Designation to Omeros' OMS824 Huntington's Disease Program
|
Read More
|
|
Feb 3, 2014
|
Omeros Announces Positive Data after Completion of Dosing in Phase 1 Clinical Trial with OMS721
|
Read More
|
|
Jan 29, 2014
|
Omeros Reports Positive Results from OMS824 Phase 2a Clinical Trial
|
Read More
|
|
Dec 18, 2013
|
FDA Grants Orphan Drug Designation to Omeros' OMS721 for Complement-Mediated Thrombotic Microangiopathies
|
Read More
|
|
Dec 5, 2013
|
Omeros to Present at Oppenheimer 24th Annual Healthcare Conference
|
Read More
|
|
Nov 20, 2013
|
Omeros Announces FDA Acceptance of Omidria™ as Proprietary Name for OMS302
|
Read More
|
|
Nov 19, 2013
|
Omeros Reports Phase 3 OMS302 Clinical Data Presented at the Annual American Academy of Ophthalmology Meeting
|
Read More
|
|
Nov 12, 2013
|
Omeros to Present Data from OMS302 Phase 3 Clinical Program at the American Academy of Ophthalmology Annual Meeting
|
Read More
|
|
Nov 7, 2013
|
Omeros Announces Positive Data in Phase 1 Clinical Trial with OMS721
|
Read More
|
|
Nov 7, 2013
|
Omeros Corporation Reports Third Quarter 2013 Financial Results
|
Read More
|
|
Nov 5, 2013
|
Omeros Announces Positive OMS721 Data in Model of Age-Related Macular Degeneration
|
Read More
|
|
Oct 17, 2013
|
Omeros Corporation Files Universal Shelf Registration Statement to Replace Expiring Universal Shelf Registration Statement
|
Read More
|
|
Oct 17, 2013
|
Omeros Reports Additional Positive Clinical Data for its Drug Candidate to Treat Cognitive Disorders
|
Read More
|
|
Oct 15, 2013
|
FDA Agrees with Omeros' Pediatric Study Plan for OMS302
|
Read More
|
|
Oct 8, 2013
|
Omeros Hires Michael K. Inouye to Lead Commercial Operations
|
Read More
|
|
Oct 3, 2013
|
Omeros Settles Insurance Litigation
|
Read More
|
|
Oct 3, 2013
|
Omeros Unlocks Six Additional Class A Orphan GPCRs and Identifies Small Molecules Targeting Two Commercially Validated Class B GPCRs
|
Read More
|
|
Oct 2, 2013
|
US and European Regulators Accept for Review OMS302 Marketing Applications
|
Read More
|
|
Sep 30, 2013
|
FDA Grants Orphan Drug Designation to Omeros' OMS824 for Huntington's Disease
|
Read More
|
|
Sep 20, 2013
|
Omeros Chosen to Present at NewsMakers in the Biotech Industry 2013 Conference
|
Read More
|
|
Sep 19, 2013
|
Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824
|
Read More
|
|
Sep 12, 2013
|
Omeros Reports Additional Positive Results from OMS824 Program
|
Read More
|
|
Sep 10, 2013
|
Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
|
Read More
|
|
Sep 9, 2013
|
Omeros to Present at the Stifel Healthcare Conference 2013
|
Read More
|
|
Aug 13, 2013
|
Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
|
Read More
|
|
Aug 9, 2013
|
Omeros Corporation Reports Second Quarter 2013 Financial Results
|
Read More
|
|
Aug 8, 2013
|
Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
|
Read More
|
|
Aug 1, 2013
|
Omeros Submits New Drug Application to U.S. FDA for OMS302
|
Read More
|
|
Jul 2, 2013
|
European Medicines Agency Approves Positive Opinion on Omeros' Pediatric Investigation Plan for OMS302
|
Read More
|
|
Jun 13, 2013
|
Omeros Obtains Regulatory Approval to Initiate Phase 1 Clinical Trial for Lead Antibody in MASP-2 Program
|
Read More
|
|
May 31, 2013
|
Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
|
Read More
|
|
May 28, 2013
|
Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program
|
Read More
|
|
May 23, 2013
|
Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease
|
Read More
|
|
May 22, 2013
|
Omeros to Present at Two Upcoming Conferences
|
Read More
|
|
May 14, 2013
|
Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
|
Read More
|
|
May 10, 2013
|
Omeros Corporation Reports First Quarter 2013 Financial Results
|
Read More
|
|
May 9, 2013
|
Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
|
Read More
|
|
May 1, 2013
|
Omeros Requests Fast Track Designation for OMS824 for the Treatment of Huntington's Disease
|
Read More
|
|
Apr 30, 2013
|
Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
|
Read More
|
|
Apr 25, 2013
|
Omeros Reports OMS302 Clinical Data Presented at the Annual ASCRS and ASOA Symposium and Congress
|
Read More
|
|
Apr 24, 2013
|
Omeros to Present at the 12th Annual Needham Healthcare Conference
|
Read More
|
|
Apr 19, 2013
|
Omeros to Present Additional OMS302 Clinical Data at the Annual ASCRS and ASOA Symposium and Congress
|
Read More
|
|
Apr 17, 2013
|
Omeros Files Orphan Drug Application for Treatment of Atypical Hemolytic Uremic Syndrome with OMS721
|
Read More
|
|
Apr 10, 2013
|
Omeros Announces that GPR17 Antagonists Improve Function in Model of Multiple Sclerosis
|
Read More
|
|
Apr 2, 2013
|
Omeros Announces Positive OMS721 Data in Model of Thrombotic Microangiopathy
|
Read More
|
|
Mar 29, 2013
|
Omeros to Present at the 2013 Future Leaders in the Biotech Industry Conference
|
Read More
|
|
Mar 28, 2013
|
Omeros Announces Toxicology Data that Support Advancing MASP-2 Inhibitor into Clinical Trials
|
Read More
|
|
Mar 26, 2013
|
Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
|
Read More
|
|
Mar 19, 2013
|
Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
|
Read More
|
|
Mar 18, 2013
|
Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
|
Read More
|
|
Mar 1, 2013
|
Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
|
Read More
|
|
Feb 7, 2013
|
Omeros Announces Toxicology Study Data from MASP-2 Inhibitor
|
Read More
|
|
Jan 22, 2013
|
Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
|
Read More
|
|
Jan 16, 2013
|
Omeros Identifies Small Molecules for Class B GPCR
|
Read More
|
|
Dec 27, 2012
|
Omeros Reports OMS103HP Phase 3 Clinical Trial Results
|
Read More
|
|
Dec 6, 2012
|
Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
|
Read More
|
|
Nov 29, 2012
|
Omeros Appoints Thomas A. Mitro as Vice President, Sales and Marketing
|
Read More
|
|
Nov 20, 2012
|
Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
|
Read More
|
|
Nov 15, 2012
|
GPR17-Targeting Compounds Identified by Omeros Promote Myelination
|
Read More
|
|
Nov 13, 2012
|
Omeros is Not Aware of Any Justification for Share Price Movement
|
Read More
|
|
Nov 9, 2012
|
Omeros Corporation Reports Third Quarter 2012 Financial Results
|
Read More
|
|
Nov 9, 2012
|
Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
|
Read More
|
|
Nov 8, 2012
|
Omeros to Present Data from Successful OMS302 Phase 3 Clinical Trial at the American Academy of Ophthalmology Annual Meeting
|
Read More
|
|
Nov 5, 2012
|
Omeros' Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
|
Read More
|
|
Nov 1, 2012
|
Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
|
Read More
|
|
Oct 24, 2012
|
Adding Four More, Omeros Has Now Unlocked 46 Orphan GPCRs
|
Read More
|
|
Oct 18, 2012
|
Omeros Adds Vice Presidents of Regulatory and Clinical to Management Team
|
Read More
|
|
Oct 3, 2012
|
Omeros Announces Completion of Enrollment in OMS302 Phase 3 Clinical Trial
|
Read More
|
|
Oct 2, 2012
|
Investigational New Drug Application Cleared for Omeros' Lead Compound in PDE10 Program
|
Read More
|
|
Sep 27, 2012
|
Arnold C. Hanish Elected to Board of Directors of Omeros
|
Read More
|
|
Sep 19, 2012
|
Omeros Awarded NIMH Grant for Development of Orphan GPCR Antibodies
|
Read More
|
|
Sep 6, 2012
|
Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
|
Read More
|
|
Sep 4, 2012
|
Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
|
Read More
|
|
Aug 15, 2012
|
Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
|
Read More
|
|
Aug 8, 2012
|
Omeros to Present at Two Upcoming Conferences
|
Read More
|
|
Aug 8, 2012
|
Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
|
Read More
|
|
Aug 7, 2012
|
Omeros Corporation Reports Second Quarter 2012 Financial Results
|
Read More
|
|
Jul 31, 2012
|
Omeros Announces Discovery in MASP-2 Program
|
Read More
|
|
Jul 18, 2012
|
Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
|
Read More
|
|
Jul 2, 2012
|
Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
|
Read More
|
|
Jun 27, 2012
|
Omeros Prices $30 Million Public Offering of Common Stock
|
Read More
|
|
Jun 26, 2012
|
Omeros Announces Proposed Public Offering of Common Stock
|
Read More
|
|
May 31, 2012
|
Omeros Announces Initiation of Planned Pharmacokinetic Substudy in OMS302 Phase 3 Clinical Program
|
Read More
|
|
May 29, 2012
|
Omeros to Present at Jefferies 2012 Global Healthcare Conference
|
Read More
|
|
May 10, 2012
|
Omeros Corporation Reports First Quarter 2012 Financial Results
|
Read More
|
|
May 3, 2012
|
Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
|
Read More
|
|
May 2, 2012
|
Omeros to Present at Deutsche Bank Securities Health Care Conference
|
Read More
|
|
Apr 10, 2012
|
Omeros Announces Enrollment in Second Phase 3 Clinical Trial Evaluating OMS302
|
Read More
|
|
Mar 29, 2012
|
Omeros Reports Allowance of Additional Patent for Ophthalmology Product OMS302
|
Read More
|
|
Mar 28, 2012
|
Omeros to Present at Two Upcoming Conferences
|
Read More
|
|
Mar 27, 2012
|
Omeros Names Dr. Patrick Gray as Scientific Fellow
|
Read More
|
|
Mar 15, 2012
|
Omeros Corporation Reports Fourth Quarter and Year-End 2011 Financial Results
|
Read More
|
|
Mar 13, 2012
|
Omeros' Ophthalmology Product OMS302 Achieves Primary and Secondary Endpoints in Phase 3 Clinical Trial
|
Read More
|
|
Mar 1, 2012
|
Omeros to Present at the Cowen and Company 32nd Annual Health Care Conference
|
Read More
|
|
Feb 29, 2012
|
Adding Six More, Omeros Now Has a Total of 33 Unlocked Orphan GPCRs in its Portfolio
|
Read More
|
|
Feb 23, 2012
|
Omeros Announces It Has Unlocked 35 Percent of Class A Orphan GPCRs
|
Read More
|
|
Feb 21, 2012
|
Omeros Awarded $1 Million NIDA Grant for NMUR2 Drug Development Program
|
Read More
|
|
Feb 8, 2012
|
Omeros to Present at the 14th Annual BIO CEO & Investor Conference
|
Read More
|
|
Feb 7, 2012
|
Omeros Provides Update on Ongoing OMS302 Phase 3 Clinical Trial
|
Read More
|
|
Feb 1, 2012
|
BioMed Realty and Omeros Sign New 64,500 Square Foot Lease in Seattle
|
Read More
|
|
Jan 10, 2012
|
Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
|
Read More
|
|
Nov 30, 2011
|
Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
|
Read More
|
|
Nov 29, 2011
|
Omeros Announces Submission to European Medicines Agency of Paediatric Investigation Plan Letter of Intent for OMS302
|
Read More
|
|
Nov 22, 2011
|
Omeros to Present at 23rd Annual Piper Jaffray Health Care Conference
|
Read More
|
|
Nov 8, 2011
|
Omeros Corporation Reports Third Quarter 2011 Financial Results
|
Read More
|
|
Oct 11, 2011
|
Omeros Announces First Patients Treated in Phase 3 Clinical Program Evaluating OMS302
|
Read More
|
|
Sep 13, 2011
|
Omeros Unlocks Four Additional Orphan GPCRs
|
Read More
|
|
Sep 6, 2011
|
Omeros to Present at Rodman and Renshaw 13th Annual Healthcare Conference
|
Read More
|
|
Aug 9, 2011
|
Omeros Corporation Reports Second Quarter 2011 Financial Results
|
Read More
|
|
Aug 3, 2011
|
Omeros to Present at Two Upcoming Conferences
|
Read More
|
|
Jun 29, 2011
|
Omeros Announces Publication of Phase 2 Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
|
Read More
|
|
Jun 27, 2011
|
Omeros Unlocks Orphan GPCRs Linked to Leukemia and Sleep Disorders
|
Read More
|
|
Jun 2, 2011
|
Omeros to Present at the Jefferies 2011 Global Healthcare Conference
|
Read More
|
|
May 31, 2011
|
Omeros Unlocks Orphan GPCR Family Linked to Metabolic and Psychotic Disorders
|
Read More
|
|
May 24, 2011
|
Omeros Reports Allowance of Additional Patent for Arthroscopic Product
|
Read More
|
|
May 19, 2011
|
Omeros Announces Clinical Development Programs for OMS103HP and OMS302
|
Read More
|
|
May 10, 2011
|
Omeros Corporation Reports First Quarter 2011 Financial Results
|
Read More
|
|
May 5, 2011
|
Omeros Announces Expansion of Potential Indications for PDE7 Inhibitors
|
Read More
|
|
Apr 27, 2011
|
Omeros to Present at Deutsche Bank Health Care Conference
|
Read More
|
|
Apr 19, 2011
|
Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
|
Read More
|
|
Apr 11, 2011
|
Omeros to Present at Future Leaders in the Biotech Industry Conference
|
Read More
|
|
Apr 7, 2011
|
Omeros Announces Publication of Data From its PPAR-gamma Addiction Program
|
Read More
|
|
Apr 4, 2011
|
Omeros to Present at Needham Healthcare Conference
|
Read More
|
|
Mar 31, 2011
|
Omeros Reports Outcome of Phase 3 Trials of OMS103HP
|
Read More
|
|
Mar 23, 2011
|
Omeros' Ophthalmology Product OMS302 Achieves Co-Primary Endpoints in Phase 2b Clinical Study
|
Read More
|
|
Mar 15, 2011
|
Omeros Corporation Reports Fourth Quarter and Year-End 2010 Financial Results
|
Read More
|
|
Mar 2, 2011
|
Omeros Unlocks Orphan GPCRs Linked to Pancreatic Cancer and Cognitive Disorders
|
Read More
|
|
Feb 22, 2011
|
Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo
|
Read More
|
|
Feb 10, 2011
|
Omeros Announces Publication of Data From Antifibrinolytic Program
|
Read More
|
|
Feb 1, 2011
|
Omeros Announces Eligibility of OMS103HP for EMA Centralized Marketing Application
|
Read More
|
|
Jan 5, 2011
|
Omeros Licenses Novel Antifibrinolytic Agents
|
Read More
|
|
Dec 29, 2010
|
Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
|
Read More
|
|
Nov 24, 2010
|
Omeros to Present at Piper Jaffray Health Care Conference
|
Read More
|
|
Nov 23, 2010
|
Omeros Announces Completion of Acquisition of Assay for GPCR Program
|
Read More
|
|
Nov 17, 2010
|
Omeros Names Dr. Kenneth Ferguson as Vice President, Development
|
Read More
|
|
Nov 9, 2010
|
Omeros Identifies Orphan GPCR-Targeting Compound Potentiating Chemotherapeutic Activity
|
Read More
|
|
Nov 4, 2010
|
Omeros Corporation Reports Third Quarter 2010 Financial Results
|
Read More
|
|
Nov 3, 2010
|
Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
|
Read More
|
|
Oct 25, 2010
|
Omeros Receives $20 Million from Vulcan Capital and $5 Million Grant Award from Washington State's Life Sciences Discovery Fund to Advance its GPCR Program
|
Read More
|
|
Oct 22, 2010
|
Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
|
Read More
|
|
Oct 15, 2010
|
Omeros to Present at the BioCentury NewsMakers Conference
|
Read More
|
|
Oct 14, 2010
|
Omeros Announces Additional Support from the National Institute on Drug Abuse for Clinical Studies in Addiction Program
|
Read More
|
|
Sep 8, 2010
|
Omeros to Present at the Rodman & Renshaw Global Investment Conference
|
Read More
|
|
Aug 10, 2010
|
Omeros Reports Second Quarter 2010 Financial Results
|
Read More
|
|
Aug 5, 2010
|
Omeros to Webcast Presentation at Canaccord Genuity 30th Annual Growth Conference
|
Read More
|
|
Jul 29, 2010
|
Omeros Secures $40 Million Committed Equity Financing Facility
|
Read More
|
|
Jul 27, 2010
|
Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
|
Read More
|
|
Jun 29, 2010
|
Omeros Successfully Unlocks Orphan GPCRs
|
Read More
|
|
Jun 3, 2010
|
Omeros To Webcast Presentation at Ninth Annual Needham Healthcare Conference
|
Read More
|
|
May 13, 2010
|
Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
|
Read More
|
|
May 12, 2010
|
Omeros Reports First Quarter 2010 Financial Results
|
Read More
|
|
May 3, 2010
|
Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
|
Read More
|
|
Apr 29, 2010
|
Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
|
Read More
|
|
Mar 31, 2010
|
Omeros Corporation Reports Fourth Quarter and Year-End 2009 Financial Results
|
Read More
|
|
Mar 31, 2010
|
Omeros Reports Phase 2 Data Showing Multiple Clinical Benefits in Patients Undergoing Arthroscopic Meniscectomy Surgery
|
Read More
|
|
Mar 15, 2010
|
Omeros Corporation to Host Conference Call on Fourth Quarter and Full Year 2009 Results on March 31
|
Read More
|
|
Mar 9, 2010
|
Omeros Licenses PDE7 Compounds for Parkinson's Disease Program
|
Read More
|
|
Jan 28, 2010
|
Omeros Announces National Institute on Drug Abuse's Support for Phase 2 Clinical Study in Addiction Program
|
Read More
|
|
Dec 9, 2009
|
Daniel K. Spiegelman Elected to Board of Directors of Omeros
|
Read More
|
|
Nov 19, 2009
|
Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
|
Read More
|
|
Nov 13, 2009
|
Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
|
Read More
|
|
Oct 7, 2009
|
Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
|
Read More
|
|
Aug 11, 2009
|
Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
|
Read More
|
|
Aug 5, 2009
|
Omeros Appoints New Vice President of Clinical Development
|
Read More
|
|
Jan 28, 2009
|
Omeros Receives $3.1 Million Milestone Payment from The Stanley Medical Research Institute for Schizophrenia Program
|
Read More
|
|
Jan 6, 2009
|
Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinson's Disease Target
|
Read More
|
|
Dec 9, 2008
|
Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
|
Read More
|
|
Sep 24, 2008
|
Omeros and BlueCrest Announce $20 Million Debt Facility
|
Read More
|
|
Sep 17, 2008
|
Omeros and The Parkinson's Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
|
Read More
|
|
Sep 9, 2008
|
Omeros Announces Patient Enrollment in Phase 1/Phase 2 Study of OMS302
|
Read More
|
|
Aug 26, 2008
|
Omeros Announces Publication of Clinical Results for OMS103HP in Arthroscopy: The Journal of Arthroscopic and Related Surgery
|
Read More
|
|
Aug 19, 2008
|
Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
|
Read More
|
|
May 20, 2008
|
Omeros Announces Initiation of Patient Enrollment in OMS201 Phase 1 Study
|
Read More
|
|
Feb 12, 2007
|
Omeros Raises More Than $63 Million in Financing
|
Read More
|
|
Jan 9, 2007
|
Omeros receives up to $9 million toward development of schizophrenia treatment
|
Read More
|
|
Sep 7, 2006
|
Omeros Acquires Nura
|
Read More
|
